Based on the Curaleaf Holdings Inc stock forecast from 5 analysts, the average analyst target price for Curaleaf Holdings Inc is CAD 7.58 over the next 12 months. Curaleaf Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Curaleaf Holdings Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Curaleaf Holdings Inc’s stock price was CAD 5.00. Curaleaf Holdings Inc’s stock price has changed by +25.31% over the past week, +25.31% over the past month and -46.41% over the last year.
No recent analyst target price found for Curaleaf Holdings Inc
No recent average analyst rating found for Curaleaf Holdings Inc
Company Overview Curaleaf Holdings Inc
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. In addition, it offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. Further, the company provides hemp-based CBD and cannabigerol products. The company was founded in 2010 and is headquartered in New York, New York. Address: 301 Edgewater Place, Wakefield, MA, United States, 01880 Read Less
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. In ad...Read More
N/A
N/A
0
N/A
CAD
Canada
Adjusted Closing Price for Curaleaf Holdings Inc (CURA:CA)
Loading...
Unadjusted Closing Price for Curaleaf Holdings Inc (CURA:CA)
Loading...
Share Trading Volume for Curaleaf Holdings Inc Shares
Loading...
Compare Performance of Curaleaf Holdings Inc Shares
Frequently Asked Questions About Curaleaf Holdings Inc (CURA:CA) Stock
Based on ratings from 5 analysts Curaleaf Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on CURA:CA's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for CURA:CA is CAD 7.58 over the next 12 months. The maximum analyst target price is CAD 17.9 while the minimum anlayst target price is CAD 2.75.
Unfortunately we do not have enough data on CURA:CA's stock to indicate if its overvalued.
The last closing price of CURA:CA's stock was CAD 5.00.
The most recent market capitalization for CURA:CA is CAD 3.30B.
Based on targets from 5 analysts, the average taret price for CURA:CA is projected at CAD 7.58 over the next 12 months.
This means that CURA:CA's stock price may go up by +51.60% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CURA:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
